Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS)

J. George, M. Blank, M. Hojnik, E. Bar-Meir, T. Koike, Eiji Matsuura, M. Lorber, M. Aviram, Y. Shoenfeld

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Ox-LDL is thought to play a major role in atherogenesis. The mechanisms mediating the deleterious influences of Ox-LDL include foam cell formation and cell cytotoxicity. The production of anti-Ox-LDL antibodies results in the formation of immune complexes which are taken up at enhanced rate by macrophages, leading to foam cell formation. APS is characterized by repeated venous and arterial thromboembolic phenomena, recurrent fetal loss and thrombocytopenia, associated with the presence of antibodies to negatively charged phospholipids (aPL) (i.e. cardiolipin, phosphatidylserine). Phospholipids bear structural resemblance to LDL, and several studies have indeed proved that aPL display cross-reactivity with anti-Ox-LDL antibodies. In this study we assessed the capacity of oxidized and native forms of LDL to aggravate the clinical picture of experimentally induced APS in naive mice. Mice were actively immunized intradermally with anticardiolipin antibodies and developed a clinical picture resembling APS in humans. Subsequently, the mice were infused with either Ox-LDL, native LDL or PBS, and similar regimens were applied to controls. APS mice infused with Ox-LDL were found to exhibit a significantly more severe form of the disease in comparison with native LDL- and PBS-infused mice, expressed by lower platelet counts (261000/mm3, 535000/mm3 and 455000/mm3, respectively), longer activated partial thromboplastin time (aPTT) (99 ± 12 s, 63 ± 8 s and 74 ± 8 s, respectively) and higher fetal resorption rates (72.7%, 34.4% and 32.6%, respectively). The results of this study show that Ox-LDL, compared with native LDL, aggravates the clinical manifestations of experimental APS and suggest that cross-reactivity of Ox-LDL with phospholipids may provide a pathogenic explanation for this effect.

Original languageEnglish
Pages (from-to)227-233
Number of pages7
JournalClinical and Experimental Immunology
Volume108
Issue number2
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Antiphospholipid Syndrome
Phospholipids
Foam Cells
oxidized low density lipoprotein
Antibodies
Fetal Resorption
Anticardiolipin Antibodies
Cardiolipins
Partial Thromboplastin Time
Phosphatidylserines
Antigen-Antibody Complex
Platelet Count
Thrombocytopenia
Atherosclerosis

Keywords

  • anticardiolipin antibodies
  • antiphospholipid syndrome
  • autoantibodies
  • autoimmunity
  • low-density lipoproteins

ASJC Scopus subject areas

  • Immunology

Cite this

George, J., Blank, M., Hojnik, M., Bar-Meir, E., Koike, T., Matsuura, E., ... Shoenfeld, Y. (1997). Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS). Clinical and Experimental Immunology, 108(2), 227-233.

Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS). / George, J.; Blank, M.; Hojnik, M.; Bar-Meir, E.; Koike, T.; Matsuura, Eiji; Lorber, M.; Aviram, M.; Shoenfeld, Y.

In: Clinical and Experimental Immunology, Vol. 108, No. 2, 1997, p. 227-233.

Research output: Contribution to journalArticle

George, J, Blank, M, Hojnik, M, Bar-Meir, E, Koike, T, Matsuura, E, Lorber, M, Aviram, M & Shoenfeld, Y 1997, 'Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS)', Clinical and Experimental Immunology, vol. 108, no. 2, pp. 227-233.
George, J. ; Blank, M. ; Hojnik, M. ; Bar-Meir, E. ; Koike, T. ; Matsuura, Eiji ; Lorber, M. ; Aviram, M. ; Shoenfeld, Y. / Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS). In: Clinical and Experimental Immunology. 1997 ; Vol. 108, No. 2. pp. 227-233.
@article{9d1238bf28804554a83478aff0b4f202,
title = "Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS)",
abstract = "Ox-LDL is thought to play a major role in atherogenesis. The mechanisms mediating the deleterious influences of Ox-LDL include foam cell formation and cell cytotoxicity. The production of anti-Ox-LDL antibodies results in the formation of immune complexes which are taken up at enhanced rate by macrophages, leading to foam cell formation. APS is characterized by repeated venous and arterial thromboembolic phenomena, recurrent fetal loss and thrombocytopenia, associated with the presence of antibodies to negatively charged phospholipids (aPL) (i.e. cardiolipin, phosphatidylserine). Phospholipids bear structural resemblance to LDL, and several studies have indeed proved that aPL display cross-reactivity with anti-Ox-LDL antibodies. In this study we assessed the capacity of oxidized and native forms of LDL to aggravate the clinical picture of experimentally induced APS in naive mice. Mice were actively immunized intradermally with anticardiolipin antibodies and developed a clinical picture resembling APS in humans. Subsequently, the mice were infused with either Ox-LDL, native LDL or PBS, and similar regimens were applied to controls. APS mice infused with Ox-LDL were found to exhibit a significantly more severe form of the disease in comparison with native LDL- and PBS-infused mice, expressed by lower platelet counts (261000/mm3, 535000/mm3 and 455000/mm3, respectively), longer activated partial thromboplastin time (aPTT) (99 ± 12 s, 63 ± 8 s and 74 ± 8 s, respectively) and higher fetal resorption rates (72.7{\%}, 34.4{\%} and 32.6{\%}, respectively). The results of this study show that Ox-LDL, compared with native LDL, aggravates the clinical manifestations of experimental APS and suggest that cross-reactivity of Ox-LDL with phospholipids may provide a pathogenic explanation for this effect.",
keywords = "anticardiolipin antibodies, antiphospholipid syndrome, autoantibodies, autoimmunity, low-density lipoproteins",
author = "J. George and M. Blank and M. Hojnik and E. Bar-Meir and T. Koike and Eiji Matsuura and M. Lorber and M. Aviram and Y. Shoenfeld",
year = "1997",
language = "English",
volume = "108",
pages = "227--233",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS)

AU - George, J.

AU - Blank, M.

AU - Hojnik, M.

AU - Bar-Meir, E.

AU - Koike, T.

AU - Matsuura, Eiji

AU - Lorber, M.

AU - Aviram, M.

AU - Shoenfeld, Y.

PY - 1997

Y1 - 1997

N2 - Ox-LDL is thought to play a major role in atherogenesis. The mechanisms mediating the deleterious influences of Ox-LDL include foam cell formation and cell cytotoxicity. The production of anti-Ox-LDL antibodies results in the formation of immune complexes which are taken up at enhanced rate by macrophages, leading to foam cell formation. APS is characterized by repeated venous and arterial thromboembolic phenomena, recurrent fetal loss and thrombocytopenia, associated with the presence of antibodies to negatively charged phospholipids (aPL) (i.e. cardiolipin, phosphatidylserine). Phospholipids bear structural resemblance to LDL, and several studies have indeed proved that aPL display cross-reactivity with anti-Ox-LDL antibodies. In this study we assessed the capacity of oxidized and native forms of LDL to aggravate the clinical picture of experimentally induced APS in naive mice. Mice were actively immunized intradermally with anticardiolipin antibodies and developed a clinical picture resembling APS in humans. Subsequently, the mice were infused with either Ox-LDL, native LDL or PBS, and similar regimens were applied to controls. APS mice infused with Ox-LDL were found to exhibit a significantly more severe form of the disease in comparison with native LDL- and PBS-infused mice, expressed by lower platelet counts (261000/mm3, 535000/mm3 and 455000/mm3, respectively), longer activated partial thromboplastin time (aPTT) (99 ± 12 s, 63 ± 8 s and 74 ± 8 s, respectively) and higher fetal resorption rates (72.7%, 34.4% and 32.6%, respectively). The results of this study show that Ox-LDL, compared with native LDL, aggravates the clinical manifestations of experimental APS and suggest that cross-reactivity of Ox-LDL with phospholipids may provide a pathogenic explanation for this effect.

AB - Ox-LDL is thought to play a major role in atherogenesis. The mechanisms mediating the deleterious influences of Ox-LDL include foam cell formation and cell cytotoxicity. The production of anti-Ox-LDL antibodies results in the formation of immune complexes which are taken up at enhanced rate by macrophages, leading to foam cell formation. APS is characterized by repeated venous and arterial thromboembolic phenomena, recurrent fetal loss and thrombocytopenia, associated with the presence of antibodies to negatively charged phospholipids (aPL) (i.e. cardiolipin, phosphatidylserine). Phospholipids bear structural resemblance to LDL, and several studies have indeed proved that aPL display cross-reactivity with anti-Ox-LDL antibodies. In this study we assessed the capacity of oxidized and native forms of LDL to aggravate the clinical picture of experimentally induced APS in naive mice. Mice were actively immunized intradermally with anticardiolipin antibodies and developed a clinical picture resembling APS in humans. Subsequently, the mice were infused with either Ox-LDL, native LDL or PBS, and similar regimens were applied to controls. APS mice infused with Ox-LDL were found to exhibit a significantly more severe form of the disease in comparison with native LDL- and PBS-infused mice, expressed by lower platelet counts (261000/mm3, 535000/mm3 and 455000/mm3, respectively), longer activated partial thromboplastin time (aPTT) (99 ± 12 s, 63 ± 8 s and 74 ± 8 s, respectively) and higher fetal resorption rates (72.7%, 34.4% and 32.6%, respectively). The results of this study show that Ox-LDL, compared with native LDL, aggravates the clinical manifestations of experimental APS and suggest that cross-reactivity of Ox-LDL with phospholipids may provide a pathogenic explanation for this effect.

KW - anticardiolipin antibodies

KW - antiphospholipid syndrome

KW - autoantibodies

KW - autoimmunity

KW - low-density lipoproteins

UR - http://www.scopus.com/inward/record.url?scp=0030982089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030982089&partnerID=8YFLogxK

M3 - Article

VL - 108

SP - 227

EP - 233

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -